Volition webinar: Nu.Q NETs data insights

Volition webinar: Nu.Q NETs data insights

VolitionRx — 7 videos in collection

More on this equity

Volition (NYSE: VNRX) and Edison recently hosted a webinar in which Volition provided insights into the data it presented at ESICM 2024, highlighting research findings from three large independent studies (over 3,000 patients) on the potential use of Volition’s Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical practice. The webinar explores the role of H3.1 nucleosomes in NETosis and why elevated levels of H3.1 are a cause for concern in sepsis patients, as well as examining how the Nu.Q NETs biomarker could predict organ failure. Volition also gave an update on its commercialisation efforts for Nu.Q NETs.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.